LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY

被引:0
|
作者
Howard, James F., Jr. [1 ]
Bril, Vera [2 ]
Tuan Vu [3 ]
Karam, Chafic [4 ]
Peric, Stojan [5 ]
De Bleecker, Jan L. [6 ]
Murai, Hiroyuki [7 ]
Meisel, Andreas [8 ,9 ]
Beydoun, Said [10 ]
Pasnoor, Mamatha [11 ]
Guglietta, Antonio [12 ]
T'joen, Caroline [12 ]
Utsugisawa, Kimiaki [13 ]
Verschuuren, Jan [14 ]
Mantegazza, Renato [15 ]
机构
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Toronto, Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[3] Univ S Florida, Morsani Coll Med, Tampa, FL USA
[4] Univ Penn, Penn Neurosci Ctr, Philadelphia, PA 19104 USA
[5] Univ Belgrade, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia
[6] Ghent Univ Hosp, Ghent, Belgium
[7] Int Univ Hlth & Welf, Sch Med, Dept Neurol, Tokyo, Japan
[8] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[9] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany
[10] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[11] Univ Kansas, Dept Neurol, Med Ctr, Kansas City, KS USA
[12] argenx, Ghent, Belgium
[13] Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Japan
[14] Leiden Univ Med Ctr, Dept Neurol, Leiden, Netherlands
[15] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:S9 / S10
页数:2
相关论文
共 50 条
  • [1] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY
    Howard, James
    Bril, Vera
    Tuan Vu
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Pasnoor, Mamatha
    Guglietta, Antonio
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Mantegazza, Renato
    [J]. MUSCLE & NERVE, 2022, 66 : S57 - S57
  • [2] Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT plus Study
    Howard, James
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Pasnoor, Mamatha
    Guglietta, Antonio
    Ulrichts, Peter
    T'joen, Caroline
    Brauer, Edward
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    [J]. NEUROLOGY, 2022, 99 (23) : S37 - S38
  • [3] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT plus Study
    Pasnoor, Mamatha
    Bril, Vera
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Vu, Tuan
    Ulrichts, Peter
    Van Hoorick, Benjamin
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James
    [J]. NEUROLOGY, 2023, 100 (17)
  • [4] Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT plus study
    Bril, Vera
    Pasnoor, Mamatha
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Vu, Tuan
    Ulrichts, Peter
    Van Hoorick, Benjamin
    T'Joen, Caroline
    Kaprielian, Roger
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James F., Jr.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [5] Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT plus study
    Ashcraft, E.
    Bril, V.
    Pasnoor, M.
    Karam, C.
    Peric, S.
    De Bleecker, J.
    Murai, H.
    Meisel, A.
    Beydoun, S.
    Vu, T.
    Ulrichts, P.
    Van Hoorick, B.
    T'joen, C.
    Utsugisawa, K.
    Verschuuren, J.
    Mantegazza, R.
    Howard, J.
    [J]. NEUROMUSCULAR DISORDERS, 2023, 33 : S179 - S179
  • [6] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
    Howard, James
    Li, George
    Vu, Tuan
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Steeland, Sophie
    Noukens, Jan
    Van Hoorick, Benjamin
    Podhorna, Jana
    Li, Yuebing
    Utsugisawa, Kimiaki
    Sacca, Francesco
    Wiendl, Heinz
    De Bleecker, Jan
    Mantegazza, Renato
    [J]. NEUROLOGY, 2023, 100 (17)
  • [7] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
    Ritt, Elissa
    Howard, James F., Jr.
    Li, George
    Vu, Tuan
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Steeland, Sophie
    Noukens, Jan
    Van Hoorick, Benjamin
    Podhorna, Jana
    Li, Yuebing
    Utsugisawa, Kimiaki
    Sacca, Francesco
    Wiendl, Heinz
    De Bleecker, Jan L.
    Mantegazza, Renato
    [J]. ANNALS OF NEUROLOGY, 2023, 94 : S244 - S245
  • [8] LONG-TERM ASSESSMENT OF EFGARTIGIMOD IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: ADAPT plus STUDY INTERIM RESULTS
    Jacob, Saiju
    Howard, James
    Bril, Vera
    Peric, Stojan
    De Bleecker, Jan
    T'joen, Carolin
    Travers, Jackalyne
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [9] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    [J]. FRONTIERS IN NEUROLOGY, 2024, 14
  • [10] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80